1. Home
  2. PDC vs GNPX Comparison

PDC vs GNPX Comparison

Compare PDC & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PDC

Perpetuals.com Ltd American Depositary Shares

N/A

Current Price

$7.00

Market Cap

13.9M

Sector

Technology

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.02

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDC
GNPX
Founded
2018
2009
Country
Japan
United States
Employees
20
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
11.8M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PDC
GNPX
Price
$7.00
$1.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
111.6K
665.0K
Earning Date
07-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.46
$0.14
52 Week High
$7.90
$12.97

Technical Indicators

Market Signals
Indicator
PDC
GNPX
Relative Strength Index (RSI) 61.44 24.62
Support Level $3.99 $0.17
Resistance Level N/A $2.12
Average True Range (ATR) 0.86 0.12
MACD 0.22 -0.01
Stochastic Oscillator 81.15 11.00

Price Performance

Historical Comparison
PDC
GNPX

About PDC Perpetuals.com Ltd American Depositary Shares

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: